shutterstock-85650661-web-1
Photo: Rob Wilson / Shutterstock.com
29 April 2014Americas

Actavis and Pfizer settle Celebrex litigation

Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Big Pharma
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
Americas
16 November 2021   Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

More on this story

Americas
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Big Pharma
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
Americas
16 November 2021   Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.

More on this story

Americas
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Big Pharma
20 April 2021   Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
Americas
16 November 2021   Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx.